Sponsor pipeline

Genprex, Inc. clinical trial pipeline

Get alerts when Genprex, Inc.'s trials change

2 active trials 2 recruiting 3 disease areas 2 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-16

What changed in the last 30 days

2026-09-12
Primary completion pushed: 2026-06 → 2027-12
Completion pushed: 2027-08 → 2028-06
NCT05703971 Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC… · Phase 1/2

Active trials by phase

Phase 1/2
2

Active trials

NCT IDTitleConditionStatusUpdated
Phase 1/2
NCT05703971 Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC… Small Cell Lung Cancer Extensive Stage Recruiting 2026-09-11
NCT04486833 Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer… Carcinoma, Non-Small Cell Lung Recruiting 2026-01-21

Disease areas by active trials

Lung Cancer (2) · Non-Small Cell Lung Cancer (NSCLC) (1) · Small Cell Lung Cancer (1)

Get alerts when Genprex, Inc.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free